These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 25723614

  • 1. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, Rosh JR, Ruemmele FM, Awni WM.
    Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
    [Abstract] [Full Text] [Related]

  • 2. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
    Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A.
    Inflamm Bowel Dis; 2017 Mar; 23(3):453-460. PubMed ID: 28129288
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Hyams JS, Dubinsky M, Rosh J, Ruemmele FM, Eichner SF, Maa JF, Lazar A, Alperovich G, Mostafa NM, Robinson AM.
    Aliment Pharmacol Ther; 2019 Jan; 49(2):155-164. PubMed ID: 30506693
    [Abstract] [Full Text] [Related]

  • 7. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [Abstract] [Full Text] [Related]

  • 8. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
    Chiu YL, Rubin DT, Vermeire S, Louis E, Robinson AM, Lomax KG, Pollack PF, Paulson SK.
    Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G, Giannini EG, Furnari M, Marabotto E, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E.
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
    Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A, Study Investigators.
    J Crohns Colitis; 2012 Mar; 6(2):160-73. PubMed ID: 22325170
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A.
    J Crohns Colitis; 2019 Sep 27; 13(10):1248-1256. PubMed ID: 30820530
    [Abstract] [Full Text] [Related]

  • 17. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec 27; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May 27; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
    Dubinsky MC, Rosh J, Faubion WA, Kierkus J, Ruemmele F, Hyams JS, Eichner S, Li Y, Huang B, Mostafa NM, Lazar A, Thakkar RB.
    Inflamm Bowel Dis; 2016 Apr 27; 22(4):886-93. PubMed ID: 26950307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.